Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma

Despite advances in deciphering the molecular pathogenesis of diffuse large B-cell lymphoma (DLBCL), patients with relapsed/refractory disease, particularly those with adverse genetic features (e.g., mutated p53 or double hit lymphoma (DHL)) have very poor prognoses, and effective therapies are lack...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wei, Chen, Juan, Tamayo, Archito T., Ruan, Changgeng, Li, Li, Zhou, Shouhao, Shen, Chan, Young, Ken H., Westin, Jason, Davis, Richard E., Hu, Shimin, Medeiros, Leonard J., Ford, Richard J., Pham, Lan V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787470/
https://www.ncbi.nlm.nih.gov/pubmed/29416618
http://dx.doi.org/10.18632/oncotarget.20378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787470/
https://www.ncbi.nlm.nih.gov/pubmed/29416618
http://dx.doi.org/10.18632/oncotarget.20378

Ejemplares similares